Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer

Endoscopy

Volumn 40, Issue 6, 2008, Pages 464-471

  Omloo, J M T ^a   Sloof, G W ^a   Boellaard, R ^b   Hoekstra, O S ^b   Jager, P L ^c   van Dullemen, H M ^c   Fockens, P ^a   Plukker, J T M ^c   van Lanschot, J J B ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG UPTAKE; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENDOSONOGRAPHY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PATIENT SELECTION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROBABILITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 46249119582     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077302     Document Type: Article

References (45)

1. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann Surg Oncol 2006; 13: 12-30
2. Lightdale CJ. Esophageal cancer. American College of Gastroenterology. Am J Gastroenterol 1999; 94: 20-29
3. van Westreenen HL, Westerterp M, Bossuyt PM et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 2004; 22: 3805-3812
4. Sobin LHWC. TNM Classifications of malignant tumors. 6th edition. New York: 2003 John Wiley & Sons,
5. Buskens CJ, Van Rees BP, Sivula A et al. Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology 2002; 122: 1800-1807
6. Koppert LB, Wijnhoven BP, Van Dekken DH et al. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005; 92: 169-190
7. Lagarde SM, ten Kate FJ, Reitsma JB et al. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 2006; 24: 4347-4355
8. Lagarde SM, ten Kate FJ, Richel DJ et al. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007; 14: 977-991
9. Flamen P, Lerut A, van Cutsem E et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202-3210
10. Kato H, Miyazaki T, Nakajima M et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148-156
11. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53: 89-112
12. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001: 42: 1S-93S
13. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004; 45: 1519-1527
14. Hoekstra CJ, Paglianiti I, Hoekstra OS et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. EurJ Nucl Med 2000; 27: 731-743
15. Krak NC, Boellaard R, Hoekstra OS et al. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 2005; 32: 294-301
16. Kroep JR, Van Groeningen CJ, Cuesta MA et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 2003; 5: 337-346
17. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004; 45: 1431-1434
18. Allal AS, Slosman DO, Kebdani T et al. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59: 1295-1300
19. Downey RJ, Akhurst T, Gonen M et al. Preoperative F-18 fluorodeoxy-glucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-3260
20. Oyama N, Akino H, Suzuki Y et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002; 4: 99-104
21. Schwarzbach MH, Hinz U, Mitrakopoulou-Strauss A et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005; 241: 286-294
22. Cerfolio RJ, Bryant AS. Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 2006; 82: 391-394
23. Rizk N, Downey RJ, Akhurst T et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006; 81: 1076-1081
24. van Westreenen HL, Plukker JT, Cobben DC et al. Prognostic value of the standardized uptake value in esophageal cancer. Am J Roentgenol 2005; 185: 436-440
25. Choi JY, Jang HJ, Shim YM et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004; 45: 1843-1850
26. van Westreenen HL, Westerterp M, Sloof GW et al. Limited additional value of positron emission tomography in staging oesophageal cancer. Br J Surg 2007; 94: 1515-1520
27. Siewert JR, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232: 353-361
28. Kwaliteitsinstituut voor de Gezondheidszorg CBO. [Richtlijn Diagnostiek en behandeling oesofaguscarcinoom]. 2005
29. Westerterp M, Pruim J, Oyen W et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 2007; 34: 392-404. Epub 2006 Oct 11
30. Atkins CD. Overestimation of the prognostic significance of SUV measurement by positron emission tomography for non-small-cell lung cancer. J Clin Oncol 2005; 23: 6799-6800
31. Borst GR, Belderbos JS, Boellaard R et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005; 41: 1533-1541
32. Eschmann SM, Friedel G, Paulsen F et al. Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer? Eur J Nucl Med Mol Imaging 2006; 33: 263-269
33. Sasaki R, Komaki R, Macapinlac H et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143
34. Hoekstra CJ, Hoekstra OS, Stroobants SG et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002; 43: 1304-1309
35. Hong D, Lunagomez S, Kim EE et al. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 2005; 104: 1620-1626
36. Marlette C, Balon JM, Maunoury V et al. Value of endoscopic ultrasonography as a predictor of long-term survival in oesophageal carcinoma. Br J Surg 2003; 90: 1367-1372
37. Ajani JA. New proposal for postsurgery pathologic staging of esophageal or gastroesophageal junction adenocarcinoma. why bother? J Clin Oncol 2007; 25: 906-907
38. de Manzoni G, Pedrazzani C, Verlato G et al. Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. Br J Surg 2004; 91: 296-303
39. Steup WH, De Leyn P, Deneffe G et al. Tumors of the esophagogastric junction. Long-term survival in relation to the pattern of lymph node metastasis and a critical analysis of the accuracy or inaccuracy of pTNM classification. J Thorac Cardiovasc Surg 1996; 111: 85-94
40. Bollschweiler E, Baldus SE, Schroder W et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 2006; 94: 355-363
41. Kutup A, Link BC, Schurr PG et al. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy 2007; 39: 715-719
42. Kato H, Kuwano H, Nakajima M et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921-928
43. Bos R, van Der Hoeven JJ, van der Wall E et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002; 20: 379-387
44. Westerterp M, Sloof GW, Hoekstra OS et al. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008; 134: 227-236 Epub 2007 Jul 25
45. Soret M, Bacharach SL, Buvat L. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48: 932-945